← All candidates
2 insider filings on record.
6 filings on record.
RNAZTranscode Therapeutics, Inc.
NasdaqCM · Healthcare · $2.27M
$2.06
-4.41% · Sep 4
2 insider filings on record.
None of them an open-market buy in the last year.
Price · 1Y · dailyNo open-market activity in range
▸ hover a marker for the filing · drag to zoom · 4 moves explained
Reverse-split 4×. When a company does a reverse split, the chart rewrites its old prices to look far bigger than they really were — so the high early prices here aren't what RNAZ ever actually traded at. The drop is real, but those huge old numbers aren't.
AI brief · from the filings on this pagePro
The filings, the score and the setup on this page, read for you in about ten seconds — what the insiders did, and what stands against it.
Market cap
$2.27M
Float
2.2M
Short % float
Pro
Institutional stakes
▸ a holder crossing 5% files Schedule 13D if they intend to act on the company, 13G if they certify they will not · /A amends an earlier filing
5 filingsnewest first
The record
newest first
Context
Coverage
EXCLUSIVE: TransCode's RNA Therapeutic Achieves 64% Stable Disease Rate In Colorectal Cancer Phase 1 StudyBenzinga · 06-03TransCode Therapeutics to Acquire Polynoma, Receive Investment from CK Life SciencesMT Newswires · 10-08Sector Update: Health Care Stocks Advance Late AfternoonMT Newswires · 10-08Sector Update: Health Care Stocks Advance Wednesday AfternoonMT Newswires · 10-08
The file stays open
6 filings on record.
The next one will be too.
▸ SEC EDGAR · FINRA · Nasdaq — public sources only · research, not advice